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Hemodialysis Twice Per Week – Single Pool Kt/V, Urea Reduction Ratio,
Blood-based Normalized Protein Catabolic Rate and Their Correlation
HL Tang, KF Yim, CMK Tang, A Cheuk, KH Chu, W Lee, KS Fung,
HWH Chan, KL Tong
Division of Nephrology, Department of Medicine and Geriatrics,
Princess Margaret Hospital, Lai Chi Kok, Hong Kong SAR, China.
Background: In Hong Kong, the majority of hemodialysis (HD) patients dialyse
two times a week. We examined the single pool Kt/V (spKt/V), urea reduction
ratio (URR) and blood-based normalized protein catabolic rate (nPCR), and
their correlation in this particular group of patients. Methods: This was a
retrospective study of 43 anuric patients who were receiving HD twice weekly.
The data from one dialysis session was retrieved from the computer system.
For all patients, the length of the HD session was 5 hours. Blood-based nPCR
was calculated from the equation: nPCR = Co/[48 + 5.14(Kt/V) + 79/(Kt/V)] +
0.168, using the pre- and post-dialysis blood urea levels of a single beginning-
of-week session of HD. spKt/V was calculated by the Daugirdas second
generation equation using the 15 seconds post-dialysis blood urea level (Stop
Pump Technique). Results: Excellent correlation existed between spKt/V and
URR, whereas weak correlation was shown between spKt/V and nPCR, and
between URR and nPCR.
r p
spKt/V vs URR 0.972 < 0.001
spKt/V vs nPCR 0.099    0.528
URR vs nPCR 0.076    0.627
Mean ( SD
spKt/V   2.0 ( 0.3
URR (%) 79 ( 5
nPCR (g/kg/day)   1.1 ( 0.3
Conclusion: In our patients receiving HD twice weekly, the mean spKt/V,
URR, and nPCR were 2.0, 79% and 1.1 g/kg/day, respectively. spKt/V and
URR correlated well, but spKt/V and URR correlated poorly with nPCR
determined from blood-based parameters.
Sevelamer Treatment Strategy in Peritoneal Dialysis Patients:
Conventional Dose Does Not Make Best Use of Resources
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Background: Given the significant incremental expense in the use of the
conventional sevelamer dose, it might be possible to benefit two to four times
as many individuals by prescribing a lower sevelamer dose. Methods: To
determine the optimum strategy of prescribing sevelamer for the treatment of
secondary hyperparathyroidism in peritoneal dialysis patients, we conducted a
6-month open-label randomized study comparing the treat-to-goal strategy
(recommended, 4.0 g daily sevelamer dose) with a lower sevelamer dose (1.2 g
daily). Results: A total of 27 peritoneal dialysis patients with serum calcium-
phosphorus product above 55 mg2/dL2 (or 4.6 mmol2/L2) were recruited and
completed the study. Nine were randomized to the treat-to-goal group (4.0 g
sevelamer daily) and 18 to the low-dose treatment group (1.2 g daily). Overall,
significantly lower calcium-phosphorus product and serum phosphorus level
at 6 months were achieved by the treat-to-goal regimen. The proportions of
patients who attained the Kidney Disease Outcomes Quality Initiative (K/DOQI)
treatment target, however, did not differ significantly between the treat-to-goal
and low-dose treatment groups (66.7 ( 30.8% vs 33.3% ( 21.8%, p = 0.10).
The numbers needed to treat in order to benefit one patient who can attain the
K/DOQI recommendation are 1.5 patients (95% CI, 1.0–2.8) in the treat-to-
goal group and three patients (95% CI, 1.8–8.7) in the low-dose treatment group.
Treat-to-goal dosing incurred mean drug acquisition costs of US$1,681 in order
to allow one patient to attain the K/DOQI target, as compared to US$1,009
with the low-dose (1.2 g) treatment strategy. In other words, an extra 66.7% of
subjects would be able to attain the treatment recommendation within the same
budget if the daily dose of sevelamer used was 1.2 g daily instead of the usual
4.0 g daily. Compared to a 1.2 g daily dose of sevelamer, 4.0 g daily had an
incremental cost-effectiveness ratio (ICER) of US$2,353 per additional patient
achieving the K/DOQI target. A multivariate analysis showed that only the
calcium-phosphorus product after 1 month of sevelamer treatment was predictive
of treatment response. Conclusion: These findings suggest that low-dose
sevelamer treatment might be a cost-effective approach, which is “good for
many rather than best for a few”.
Spironolactone is not Effective for the Treatment of Hypokalemia in
Peritoneal Dialysis Patients
JSS Kwok, KM Chow, BCH Kwan, PKT Li, CC Szeto
Department of Medicine and Therapeutics, Prince of Wales Hospital,
The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
Background: Hypokalemia is a common problem in patients on continuous
ambulatory peritoneal dialysis (CAPD). We evaluated the efficacy and safety
of spironolactone for the treatment of hypokalemia in CAPD patients. Methods:
We reviewed the clinical response of 12 consecutive hypokalemic CAPD
patients treated with spironolactone in our center. Results: All patients received
spironolactone 25 mg daily. There was no significant change in the serum
potassium level after administration of spironolactone (3.30 ( 0.26 to 3.46 (
0.38 mmol/L, p = 0.28), although regular oral potassium supplement was
required in only three patients. There was also no significant change in arterial
blood pressure or urine output after spironolactone treatment. Spironolactone
was well tolerated and no incident of hyperkalemia was recorded. Conclusion:
Spironolactone is not effective in the treatment of hypokalemia in stable CAPD
patients, but the agent is well tolerated. Future studies are warranted to determine
the therapeutic role of spironolactone in CAPD patients with concomitant
congestive heart failure or cardiovascular diseases.
Prevalence of Psychological Problems in Chinese Peritoneal
Dialysis Patients
KY Chung, CC Szeto, KM Chow, MC Law, CB Leung, PKT Li
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Background: Psychological problems are common among dialysis patients.
We studied the prevalence of psychological problems in a cohort of Chinese
peritoneal dialysis (PD) patients. Methods: We studied 167 unselected adult
PD patients from a single dialysis unit. Psychological status and social support
were assessed by the Hospital Anxiety and Depression Scale (HADS) and the
Medical Outcomes Study Social Support Survey, Chinese Version (MOS-SSS-
C) questionnaires, respectively. Results: With the HADS questionnaire, 33
(20.0%) and 76 (45.5%) patients had at least mild anxiety and depression
symptoms, respectively. With the MOS-SSS-C questionnaire, 13.8% of patients
had borderline social support, and 4.2% had poor social support. There was a
close internal correlation between the HADS and MOS-SSS-C scores. A higher
HADS score was noted in male patients (8.19 ( 6.80, p = 0.038), elderly patients
(r = 0.224, p = 0.011), patients partly dependent with regard to their daily
activities (8.35 ( 4.63 vs 7.08 ( 4.12, p = 0.08), those with no full-time job
(7.47 ( 4.31 vs 4.45 ( 2.16, p = 0.003), those not on transplant waiting lists
(7.90 ( 4.33 vs 5.71 ( 3.82, p = 0.008), and those with poor drug compliance
(7.80 ( 4.44 vs 4.25 ( 4.17, p = 0.016). Conclusion: Psychological symptoms
are highly prevalent in Chinese PD patients. Depressive symptoms are common
in elderly male patients without full-time jobs and patients not on transplant
waiting lists. On the other hand, anxiety symptoms and poor social support are
associated with poor compliance to various aspects of treatment.
